The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study.
MCP-1
Migraine
Nano-curcumin
Resistin
Serum levels
Visfatin
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
20
01
2022
accepted:
11
05
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
26
5
2022
Statut:
epublish
Résumé
The present study aimed to investigate the effects of nano-curcumin supplementation on adipokines levels and clinical signs in obese and overweight patients with migraine. Forty-four patients with episodic migraine participated in this clinical trial and were divided into two groups nano-curcumin (80 mg/day) and the control group over 2-month period. At the baseline and the end of the research, the serum levels of MCP-1, Resistin, and Visfatin were measured using the ELISA method. In addition, the headache attack frequencies, severity, and duration of pain were recorded. The results of the present study showed that nano-curcumin can significantly reduce MCP-1 serum levels in the nano-curcumin supplemented group (P = 0.015, size effect = 13.4%). In the case of resistin and visfatin, nano-curcumin supplementation exerted no statistically significant changes in serum levels (P > 0.05). Nano-curcumin also significantly reduced the attack frequencies, severity, and duration of headaches (P < 0.05). These findings indicate that targeting curcumin can be a promising approach to migraine management. However, further comprehensive human trials are needed to confirm these findings. This study was registered in the Iranian Registry of Clinical Trials (IRCT) with ID number: IRCT20160626028637N2 on the date 2020-07-10.
Identifiants
pubmed: 35606882
doi: 10.1186/s13104-022-06074-4
pii: 10.1186/s13104-022-06074-4
pmc: PMC9125853
doi:
Substances chimiques
Adipokines
0
Resistin
0
Nicotinamide Phosphoribosyltransferase
EC 2.4.2.12
Curcumin
IT942ZTH98
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Informations de copyright
© 2022. The Author(s).
Références
Headache. 2009 Feb;49(2):170-7
pubmed: 18783447
Eur Cell Mater. 2017 May 09;33:279-293
pubmed: 28485773
Sci Rep. 2015 May 18;5:9862
pubmed: 25985292
Neurochem Res. 2015 Mar;40(3):463-72
pubmed: 25479948
Brain Behav. 2018 Jun;8(6):e00950
pubmed: 30106228
ScientificWorldJournal. 2014 Feb 11;2014:898361
pubmed: 24678280
Neurobiol Dis. 2017 May;101:16-26
pubmed: 28108291
Neurology. 2015 Apr 7;84(14):1409-18
pubmed: 25746563
Med Sci Monit. 2017 Jan 03;23:24-28
pubmed: 28044053
CNS Neurol Disord Drug Targets. 2018;17(6):430-438
pubmed: 29938621
Int Immunopharmacol. 2014 Sep;22(1):230-5
pubmed: 24998635
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Biomed Pharmacother. 2016 Aug;82:578-82
pubmed: 27470399
Cancer Chemother Pharmacol. 2012 Jan;69(1):65-70
pubmed: 21603867
Sci Rep. 2015 May 19;5:10278
pubmed: 25988362
Headache. 2006 Mar;46(3):503-7
pubmed: 16618270
Endocrinology. 2012 Feb;153(2):554-63
pubmed: 22186408
Expert Opin Drug Saf. 2013 Sep;12(5):621-9
pubmed: 23815562
Cephalalgia. 2009 Mar;29(3):365-72
pubmed: 19175774
Atherosclerosis. 2009 Jul;205(1):113-9
pubmed: 19166999
Rheumatology (Oxford). 2013 Dec;52(12):2218-22
pubmed: 24026247
J Womens Health (Larchmt). 2018 Aug;27(8):965-973
pubmed: 30129895
J Immunol. 2005 May 1;174(9):5789-95
pubmed: 15843582
Neurology. 2007 May 22;68(21):1851-61
pubmed: 17515549
J Neuroimmunol. 2006 Feb;171(1-2):184-8
pubmed: 16325275
Phytother Res. 2011 Dec;25(12):1737-42
pubmed: 21442673
Pain. 1983 Sep;17(1):45-56
pubmed: 6226917
Br J Anaesth. 2013 Oct;111(4):667-72
pubmed: 23719767
Acta Cir Bras. 2016 Nov;31(11):706-713
pubmed: 27982256
J Cell Biochem. 2017 Dec;118(12):4170-4182
pubmed: 28485496
Endocr Metab Immune Disord Drug Targets. 2019;19(6):874-884
pubmed: 30760195
Cephalalgia. 2017 Oct;37(11):1067-1073
pubmed: 27553954
BMC Res Notes. 2021 Jul 23;14(1):283
pubmed: 34301320
Cytokine Growth Factor Rev. 2017 Feb;33:55-63
pubmed: 27743775